Ascendiant Capital Markets Issues Pessimistic Forecast for PAVmed (NASDAQ:PAVM) Stock Price

PAVmed (NASDAQ:PAVM) had its target price dropped by investment analysts at Ascendiant Capital Markets from $21.00 to $19.00 in a research note issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

PAVmed Price Performance

Shares of NASDAQ:PAVM opened at $0.85 on Monday. The company has a 50 day moving average of $1.07 and a 200-day moving average of $1.06. PAVmed has a one year low of $0.60 and a one year high of $4.44. The stock has a market cap of $9.41 million, a price-to-earnings ratio of -0.20 and a beta of 0.67.

About PAVmed

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.